Holdbrook Mark J. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 21, 2023
Insider Transaction Report
Form 4
Holdbrook Mark J.
V.P., Clinical Affairs
Transactions
- Sale
Common Stock
2023-03-17$13.28/sh−188$2,497→ 3,389 total - Sale
Common Stock
2023-03-20$12.61/sh−198$2,497→ 3,191 total
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.